Cagrilintide Peptide For Sale

Buy Cagrilintide peptide: 5mg, 10mg or 20mg listed purchase quantities. Compare live prices across 12 listed vendors with real cost per mg, recorded COA availability and discount codes.

Buy Cagrilintide peptide starting at $39.60/purchase from 12 listed vendors. Compare 5mg, 10mg and 20mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).

How much does Cagrilintide cost per month?

An illustrative Cagrilintide cost model works out to about $6.50 per month: Ascension Peptides's listed 10 mg purchase quantity at $50.00 with code WPA, divided into 0.3 mg amounts once weekly. This quantity provides 33.3 nominal portions — about 33.3 weeks at the selected cadence, before preparation losses or stability limits — for roughly $1.50 per week or $6.50 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 2,746 calculator runs; overall cadence comes from 274 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.

Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.

About Cagrilintide

In clinical trialsAlso known as: AM833

Cagrilintide is a long-acting amylin-analog research peptide most often sourced for weight-management research, frequently paired with semaglutide. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

What to check before you buy Cagrilintide:

  • A third-party COA showing ≥99% purity by HPLC plus mass-spec confirmation of the peptide mass — important for a newer molecule where mislabeling and impure synthesis are a bigger risk.
  • A COA dated within the last 6–12 months tied to the specific batch and vial size you are ordering.
  • Accurate vial fill matching the label (a 10mg vial assaying near 10mg). Under-filled vials are a common failure mode, and they skew your dosing math.

A 26-week Phase 2 trial (Lau et al., Lancet 2021) in 706 adults with obesity reported ~10.8% mean weight reduction on cagrilintide 4.5mg monotherapy versus 3.0% on placebo.[2] A Phase 1b combination study with semaglutide (Enebo et al., Lancet 2021) found ~17.1% weight loss at 20 weeks — driving the move to the REDEFINE Phase 3 program comparing CagriSema head-to-head against tirzepatide.[3]

Regulatory: Not FDA-approved. Phase 3 REDEFINE program ongoing as the CagriSema (cagrilintide + semaglutide) fixed combination. Cagrilintide monotherapy is not in active development.

Read the full mechanism & research breakdown

Cagrilintide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Cagrilintide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Cagrilintide is a long-acting synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin by pancreatic β-cells. Endogenous amylin is short-lived — its half-life is roughly 13 minutes — so Novo Nordisk built cagrilintide around a fatty-acid sidechain that binds serum albumin, extending the half-life to approximately 159 hours and supporting once-weekly subcutaneous dosing.[2] Amylin signals through heterodimeric receptors made from the calcitonin receptor paired with receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3), known as AMY1, AMY2, and AMY3.[4] Cagrilintide is an agonist at both the amylin receptors and the calcitonin receptor, and this dual activity in the area postrema, nucleus tractus solitarius, and hypothalamic arcuate nucleus slows gastric emptying, suppresses post-meal glucagon, and increases satiety — pharmacology that complements (rather than duplicates) GLP-1 receptor agonism.[9] That mechanistic complementarity is the rationale for the fixed-combination CagriSema (cagrilintide + semaglutide), which is the molecule's primary development path.

Active research areas

  • Obesity without diabetes (REDEFINE 1)
    The flagship Phase 3 trial reported that CagriSema produced approximately 20.4% mean weight reduction at 68 weeks in adults with overweight or obesity but without diabetes, versus 3.0% on placebo — placing it in the same range as tirzepatide in the SURMOUNT-1 trial, but without a head-to-head comparator in the trial design.[5]
  • Obesity with type 2 diabetes (REDEFINE 2)
    REDEFINE 2 reported approximately 13.7% mean weight reduction at 68 weeks in adults with T2D and obesity on CagriSema, with A1C reductions of roughly 1.8% — somewhat below the magnitude seen in the non-diabetic population, consistent with the broader pattern of incretin therapies producing less weight loss in T2D.[6]
  • Cardiovascular outcomes (REDEFINE 3)
    A long-running outcomes trial in adults with obesity and established cardiovascular disease testing whether CagriSema reduces the composite of cardiovascular death, non-fatal MI, and non-fatal stroke, building on the SELECT precedent for semaglutide alone.[7]
  • Cagrilintide monotherapy (Phase 2, historical)
    A 26-week Phase 2 dose-finding trial in 706 adults with obesity reported ~10.8% mean weight reduction on cagrilintide 4.5mg monotherapy versus 3.0% on placebo and ~9.0% on liraglutide.[2] Novo Nordisk has not advanced the monotherapy program beyond Phase 2; the strategic bet is on the fixed combination with semaglutide.
  • Amylin / GLP-1 mechanistic complementarity (Phase 2)
    A Phase 2 active-controlled trial in T2D directly compared CagriSema against semaglutide 2.4mg monotherapy and reported additive benefit on weight loss with no meaningful increase in nausea or vomiting versus semaglutide alone — supporting the hypothesis that amylin agonism reduces the GI side-effect cost of high-dose GLP-1 agonism.[10]
Open questions & leading hypotheses (3)
  • Hypothesis: CagriSema produces weight loss equivalent to or greater than tirzepatide, and the amylin arm gives it an advantage on body composition or GI tolerability.
    Evidence: The REDEFINE 1 placebo-adjusted weight loss (~20.4%) is in the same range as tirzepatide in SURMOUNT-1 (~20.9%).[5] Phase 2 data suggest the amylin arm may blunt the nausea/vomiting cost of high-dose GLP-1 agonism.[10] Counter-evidence: REDEFINE 1 did not include a tirzepatide comparator arm, so any head-to-head claim is indirect; a properly powered direct comparison is not yet published, and the magnitude of weight loss with CagriSema in the diabetic population (REDEFINE 2, ~13.7%) is below the corresponding tirzepatide trial (SURMOUNT-2, ~15.7%).[6]
  • Hypothesis: Cagrilintide is a meaningful monotherapy weight-loss agent on its own and would be commercially viable without semaglutide.
    Evidence: The Phase 2 monotherapy trial reported placebo-adjusted weight loss of roughly 7–8% at 26 weeks at the 4.5mg dose, broadly comparable to early-class GLP-1 monotherapy data and the older short-acting amylin analog pramlintide.[2][8] Counter-evidence: Novo Nordisk has not advanced cagrilintide monotherapy past Phase 2, signalling that the company sees the strategic value as the fixed combination; the monotherapy weight loss is materially smaller than that achieved by GLP-1 monotherapy at the same trial duration.
  • Hypothesis: Amylin agonism preserves more lean mass than GLP-1 agonism during weight loss, because it works primarily through satiety rather than through reduced caloric intake driven by nausea.
    Evidence: Pre-clinical work and the mechanistic profile in Hay et al. support that amylin agonists slow gastric emptying without the strong central nausea/vomiting that drives much of GLP-1's acute appetite suppression.[4][9] Counter-evidence: published body-composition substudies from the REDEFINE program have not yet demonstrated a clear lean-mass advantage for CagriSema over semaglutide monotherapy; the question is mechanistically plausible but not empirically settled.
What community users report

Anecdotal — not controlled-trial evidence

On r/Cagrilintide and the cagrilintide-tagged threads in r/Semaglutide, users running self-directed research-grade protocols most often describe satiety that feels distinct from semaglutide — described as a faster "full" signal during meals rather than a global suppression of appetite — and a side-effect profile dominated by mild nausea, constipation, and a transient anorexia-like effect that resolves with titration.[11][12] A consistent thread is users adding low-dose cagrilintide to existing semaglutide or tirzepatide protocols specifically to break through weight-loss plateaus, with self-reported additional weight loss of 1–3lb per week during the loading phase. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what self-experimenters notice but do not establish that any specific stacking protocol is safe or effective; the only properly controlled human data for cagrilintide come from Novo Nordisk's registered Phase 2 and Phase 3 program.

Sources & references (12)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]ClinicalTrials.gov: REDEFINE 1 (NCT05567796) — CagriSema in adults with overweight or obesity. link
  2. [2]Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160–2172. · PMID: 34798060 link
  3. [3]Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021;397:1736–1748. · PMID: 33894838 link
  4. [4]Hay DL et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 2015;67:564–600. · PMID: 26071095 link
  5. [5]Novo Nordisk company announcement — REDEFINE 1 Phase 3 headline results for CagriSema in adults with overweight or obesity without type 2 diabetes, December 2024. link
  6. [6]ClinicalTrials.gov: REDEFINE 2 (NCT05394519) — CagriSema in adults with type 2 diabetes and overweight or obesity. link
  7. [7]ClinicalTrials.gov: REDEFINE 3 (NCT05669755) — Cardiovascular outcomes with CagriSema in overweight or obesity and established cardiovascular disease. link
  8. [8]FDA prescribing information for Symlin (pramlintide acetate) — short-acting amylin analog approved 2005 as adjunctive insulin therapy. link
  9. [9]Mathiesen DS et al. Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat. Front Endocrinol 2020;11:617400. · PMID: 33488526 link
  10. [10]Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023;402:720–730. · PMID: 37364590 link
  11. [11]Community report — r/Cagrilintide weekly experience and dose-titration threads (subreddit), accessed May 2026. link
  12. [12]Community report — r/Semaglutide CagriSema and amylin-stack discussions (subreddit), accessed May 2026. link

What Cagrilintide Costs Right Now

WPA currently tracks Cagrilintide from 12 distinct vendors across 18 separate Cagrilintide listings. In-stock Cagrilintide vials run from $39.60 to $224.99 — a 5.7x spread for the same compound. EZ Peptides holds the lowest sticker price at $39.60. Normalized to milligrams, Cagrilintide costs $5.00/mg to $18.00/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.

Cagrilintide is stocked in 3 sizes: 10 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Cagrilintide listings WPA tracks are: Ascension Peptides — 10mg at $50 ($5.00/mg), COA purity 98.86%; Modified Aminos — 10mg at $62.99 ($6.30/mg), COA purity 98.80%; Ameano Peptides — 10mg at $79.20 ($7.92/mg), COA purity 99.95%; EZ Peptides — 10mg at $79.20 ($7.92/mg), COA purity 99.13%; EZ Peptides — 5mg at $39.60 ($7.92/mg), COA purity 99.88%.

Cagrilintide COA Coverage Across Tracked Vendors

17 of the 18 tracked Cagrilintide listings (94%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 17 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 98.80% to 99.95%. 15 listings record more Cagrilintide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 10/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Cagrilintide offer. WPA's listing fields do not establish that a report was independently verified.

Cagrilintide Calculator Input Observations

In lifetime Cagrilintide calculator inputs, 250mcg is the most frequent entered amount (636 of 2,746 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (197 of 274 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Weekly (1x/wk) is most frequent (65 of 90 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 20 mg of listed product divided by 0.25 mg gives roughly 80 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Cagrilintide Discount Codes

18 of the 18 tracked Cagrilintide listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Cagrilintide

Cagrilintide is a long-acting amylin-analog research peptide most often sourced for weight-management research, frequently paired with semaglutide. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.

Cagrilintide is tracked under the Weight Loss category on WPA. Its reported half-life is ~7 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.

How to Read the Cagrilintide Comparison

  • Price per milligram — Every Cagrilintide listing is normalized to $5.00/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 17 Cagrilintide listings are marked for COA availability, and 17 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The Cagrilintide comparison includes 5mg, 10mg, and 20mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each Cagrilintide listing, refreshed on a recurring basis.

Frequently Asked Questions: Cagrilintide

Is it legal and safe to buy Cagrilintide for research?

In the US, Cagrilintide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Cagrilintide is an investigational long-acting amylin analog with no approved human form anywhere, sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 18 Cagrilintide listings from 12 vendors.

How do I verify a Cagrilintide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Cagrilintide batch. Check that the report identifies the compound (actually cagrilintide, not semaglutide, tirzepatide, or a cagri/sema blend), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Cagrilintide specifically, 17 of 18 tracked listings (94%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 17 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 10/26.

Which Cagrilintide vendor should I pick?

There's no single "best" Cagrilintide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Cagrilintide is often paired or confused with GLP-1s, so confirm the COA names cagrilintide specifically and isn't a blend. 12 vendors currently carry Cagrilintide, and Ascension Peptides holds the best true value at $5.00/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Cagrilintide cost — and how do I know I'm not overpaying?

Judge Cagrilintide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It commonly ships in 5 mg and 10 mg vials, and the larger sizes win on $/mg over a full titration. Tracked Cagrilintide listings currently run $5.00/mg to $18.00/mg across 5mg, 10mg, 20mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Cagrilintide do I need for one full cycle?

In lifetime Cagrilintide calculator inputs, 250mcg is the most frequent entered amount (636 of 2,746 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (197 of 274 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Weekly (1x/wk) is most frequent (65 of 90 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 20 mg purchase quantity by 0.25 mg gives roughly 80 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Cagrilintide?

Participating Cagrilintide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 18 of the 18 tracked Cagrilintide listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Where can I compare Cagrilintide prices and listing details?

This comparison shows 18 tracked listings for Cagrilintide in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.